Music therapy: A nonpharmacological approach to the care of agitation and depressive symptoms for nursing home residents with dementia

Dementia: Published online October 29, 2015


music therapy

Depression, agitation, and wandering are common behaviors associated with dementia and frequently observed among nursing home residents. Even with pharmacological treatment, behaviors often persist, hindering quality of life for elders, their family, and paid caregivers.

This study examined the use of music therapy for treatment of these symptoms among 132 people with moderate to severe dementia in nursing homes. Participants were evaluated for depressive symptoms, agitation, and wandering to determine their predominate behavior. There were two assessments, two weeks apart, prior to intervention, followed by a two-week intervention, and two follow-up assessments, also two weeks apart. A repeated measures ANOVA determined that after two weeks of music therapy, symptoms of depression and agitation were significantly reduced; there was no change for wandering.

Multivariate analyses confirmed a relationship between music therapy and change in neuropsychiatric symptoms associated with dementia. Results suggest widespread use of music therapy in long-term care settings may be effective in reducing symptoms of depression and agitation.

via Music therapy: A nonpharmacological approach to the care of agitation and depressive symptoms for nursing home residents with dementia.

Dementia Drug Effective in Helping Avoid Transitions into Care Homes

Analysis of data from the DOMINO-AD Trial indicates that the drug Donepezil may be effective in avoiding care home admissions in more advanced cases of Alzheimer’s Disease. Discontinuation of donepezil appears to be associated with an increased risk of nursing home admissions in community-living patients with moderate-to-severe Alzheimer’s Disease during the first 12 months following drug cessation.

Full reference: Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO-AD) trial: secondary and post-hoc analyses. The Lancet Neurology. [Epub ahead of print].

Related: Dementia drug ‘keeps patients out of nursing homes’ BBC News

Dementia—not all about Alzheimer’s

Latest Health News

The Lancet: Volume 386, No. 10004, p1600, 24 October 2015

non-alzheimers-dementia-sml

Dementia resulting from Alzheimer’s disease has catapulted into the public’s consciousness in the past few years. However, dementia has many causes—not just Alzheimer’s, and the symptoms of non-Alzheimer’s dementias can be very different. A three-paper Series in The Lancet summarises the most common non-Alzheimer’s disorders that cause dementia. In the first, Jee Bang and colleagues discuss frontotemporal dementia. The disorder has three variants: behavioural-variant, associated with behavioural deficits; non-fluent variant primary progressive aphasia, with language deficits; and semantic-variant primary progressive aphasia, a disorder of semantic knowledge and naming.

Related Series:

Non-Alzheimers dementia: The Lancet, Published: October 23, 2015
Non-Alzheimer’s dementias remain relatively unknown and often poorly diagnosed. More research is needed, not only for effective pharmacological interventions with disease-modifying effects, but also better differential diagnostic techniques to ensure the proper management and care of patients. A Series of three papers summarises…

View original post 88 more words

Marked gender differences in progression of mild cognitive impairment over 8 years

Alzheimer’s & Dementia: September 2015 Volume 1, Issue 2, Pages 103–110

Abstract
Introduction
This study examined whether, among subjects with mild cognitive impairment (MCI), women progressed at faster rates than men.

Methods
We examine longitudinal rates of change from baseline in 398 MCI subjects (141 females and 257 males) in the Alzheimer’s Disease Neuroimaging Initiative-1, followed for up to 8 years (mean, 4.1 ± 2.5 years) using mixed-effects models incorporating all follow-ups (mean, 8 ± 4 visits).

Results
Women progressed at faster rates than men on the Alzheimer’s disease assessment scale-cognitive subscale (ADAS-Cog; P = .001) and clinical dementia rating-sum of boxes (CDR-SB; P = .003). Quadratic fit for change over time was significant for both ADAS-Cog (P = .001) and CDR-SB (P = .004), and the additional acceleration in women was 100% for ADAS-Cog and 143% for CDR-SB. The variability of change was greater in women. The gender effect was greater in apolipoprotein E (APOE) ε4 carriers.

Discussion
Women with MCI have greater longitudinal rates of cognitive and functional progression than men. Studies to confirm and uncover potential mechanisms appear to be warranted.

The deviousness of dementia

Latest Health News

By Dasha Kiper | The Guardian

In November 2010, when I was 25 years old, I moved in with a man who was 98. This man, whom I’ll call Mr Schecter, wasn’t a friend or relation or anyone I knew. He was a Holocaust survivor in the first stages of dementia, and I’d been hired to look after him. Although my background was in clinical psychology, I was by no means a professional caregiver. I was employed because Mr Schecter’s son – I’ll call him Sam – had seriously underestimated his father’s condition. Sam’s mistake was understandable. The most obvious paradox of dementia is the victim’s frequent inability to recognise it, and Mr Schecter went about his life as though burdened by the normal aches and pains of aging rather than by an irrevocable and debilitating illness. If he put the laundry detergent in the oven or forgot which floor he…

View original post 173 more words